Vir Therapy with Elebsiran High Virologic Response and ALT Normalization in Hepatitis D

 

• Preliminary Phase 2 SOLSTICE trial data reinforce the potential of both regimens to be transformative treatments in an area of high unmet medical need
• Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST

A live webcast of the June 5 investor call will be made available on https://investors.vir.bio and a recording will be archived there for 30 days.

The EASL oral scientific presentation will be made available under Events & Presentations in the Investors section of the Vir website following the presentation on June 8^th.

https://www.biospace.com/article/releases/tobevibart-monotherapy-and-combination-therapy-with-elebsiran-achieved-high-virologic-response-and-alt-normalization-in-people-living-with-the-hepatitis-delta-virus-after-12-and-24-weeks-of-treatment/